Handelsavisen
prelaunch
Companies ›Healthcare ›PHNU.MI
PH
PHNU.MI — Borsa Italiana Pharmaceuticals

Pharmanutra SpA

€89,90
Open in Charts → Attach watcher ⌖
— —
EUR
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
1,33 %
Op margin
—
ROE
—
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Pharmanutra SpA is a pharmaceutical company that develops and commercializes nutraceutical and pharmaceutical products, primarily in the personal care and wellness segments.

Business. Pharmanutra SpA (PHNU.MI) is a pharmaceutical company headquartered in Italy that operates within the Healthcare sector. The firm is primarily listed on the Borsa Italiana. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY3 analysts
3 buy0 hold0 sell
Avg 12m price target87,00

Analyst recommendations

3 analysts · consensus Buy
Buy3
Hold0
Sell0
12-month price target
87,00
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
3 analysts · indicative
Ownership
—
not yet wired
Profitability
—
not yet wired
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning PHNU.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to PHNU.MI. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Pharmanutra SpA (PHNU.MI) is a pharmaceutical company headquartered in Italy that operates within the Healthcare sector. The firm is primarily listed on the Borsa Italiana. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    Pharmanutra SpA has a fully diluted share count of 9,575,183 shares, with no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible instruments. The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

    The company's profitability metrics are not available in the current valuation snapshot, and no industry-specific preferred metrics are provided in the industry_config. As a result, a direct comparison to cohort medians for profitability and returns is not possible at this time.

    Pharmanutra's revenue concentration by segment and geography is not disclosed in the available data. The company operates in the pharmaceutical and personal care products industry, but no specific geographic or segment breakdown is provided in the input data.

    The company's growth trajectory is not quantified in the outlook section, and no numeric deltas are provided for the current or next fiscal year. Analysts have assigned a mean price target of 87.00 EUR, with a median of 87.00 EUR, and a mean recommendation of 1.67, indicating a generally positive outlook.

    The risk assessment indicates a low dilution risk, with no near-term dilution pressure identified. No specific dilution sources are disclosed in the input data, and no adjustments have been applied to the valuation metrics.

    No recent events, such as filings or transcripts, are provided in the input data to inform the company's current strategic or operational developments.

    Key takeaways
    • Pharmanutra SpA has no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible instruments.
    • Analysts have assigned a generally positive outlook, with a mean price target of 87.00 EUR and a mean recommendation of 1.67.
    • The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
    • No specific revenue concentration by segment or geography is disclosed in the available data.
    • No growth trajectory or numeric deltas are provided for the current or next fiscal year.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    ANNUALFiled 2026-03-17
    FY 2026 · Full-year highlights

    Revenue €131.7M, +14,0% YoY; Operating income +10,7% YoY.

    Revenue€131.7M+14,0 % YoY
    Operating income€30.3M+10,7 % YoY
    Net income€20.0M+20,4 % YoY
    Free cash flow€10.6M+44,1 % YoY
    EPS—
    Operating cash flow€19.6M−4,2 % YoY
    Financials
    Income statement
    Revenue€131.7M
    Gross profit€127.3M
    Operating income€30.3M
    Net income€20.0M
    Margins
    Gross margin96.7%
    Operating margin23.0%
    Net margin15.2%
    FCF margin8.1%
    Balance sheet
    Total assets€125.2M
    Total liabilities€53.9M
    Total equity€71.4M
    Cash & equivalents—
    Long-term debt€20.5M
    Cash flow
    Operating cash flow€19.6M
    CapEx-€3.1M
    Free cash flow€10.6M
    SBC—
    P&L flow · revenue → net income
    Revenue €131.7MOperating costs €101.4MTax €10.3MNet income €20.0M
    Highlights
    • ▍Revenue €131.7M, +14,0% YoY
    • ▍Operating income +10,7% YoY
    • ▍Net income +20,4% YoY
    • ▍Free cash flow +44,1% YoY
    • ▍Net margin 15.2%

    Valuation FY

    Market price
    €89,90
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    —
    Net cashⓘ
    —
    Current ratioⓘ
    —
    Debt / equityⓘ
    —
    ROAⓘ
    —
    ROEⓘ
    —
    Cash conversionⓘ
    —
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    2,54
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    3
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-05-16 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate2,54
    Revenue—no estimate—no estimate151,8M EUR
    Operating income—no estimate—no estimate36,1M EUR
    Full-year consensus mean (period as reported by source) · consensus in EUR. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution3 analysts
    Strong buy1
    Buy2
    Hold0
    Sell0
    Strong sell0
    12-month price target€87,00 · Median €87,00
    Low €85,00High €89,00
    Operating income · consensus36,1M EUR
    EPS surprise
    −17,7 %
    reported vs consensus · miss
    Revenue surprise
    −13,3 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low€85,00
    Mean€87,00
    Median€87,00
    High€89,00
    Spot€89,90
    −3.2 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    Source documents
    • Pharmanutra SpA Market data — financials · 2026-05-28
    • Pharmanutra SpA Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Leadership

    • Andrea LacorteExecutive Chairman of the Board

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    PHNU.MICanonical
    Borsa Italiana · EUR

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-03-17 16:43 UTCEARNINGSQuarterly results — Q4 2025
    2026-03-17 16:43 UTCEARNINGSAnnual results — FY 2026 Revenue EUR 131.7M · Net EUR 20.0M
    2025-03-14 16:35 UTCEARNINGSQuarterly results — Q4 2024
    2025-03-14 16:35 UTCEARNINGSAnnual results — FY 2025 Revenue EUR 115.5M · Net EUR 16.6M
    2024-11-11 14:33 UTCEARNINGSQuarterly results — Q3 2024 Revenue EUR 27.4M · Net EUR 4.3M
    2024-03-15 16:46 UTCEARNINGSAnnual results — FY 2024 Revenue EUR 100.2M · Net EUR 12.8M
    2023-03-16 17:14 UTCEARNINGSAnnual results — FY 2023 Revenue EUR 82.7M · Net EUR 15.0M
    2022-03-18 19:57 UTCEARNINGSAnnual results — FY 2022 Revenue EUR 68.1M · Net EUR 13.8M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage